3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Carcinoma, Hepatocellular
9
Neoplasms
8
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Nasopharyngeal Carcinoma
6
Triple Negative Breast Neoplasms
5
Esophageal Neoplasms
5
Neoplasm Metastasis
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Recurrence
3
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Stomach Neoplasms
2
Solid Cancers
2
Small Cell Lung Carcinoma
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Gastric / Gastroesophageal Junction Adenocarcinoma
2
EBV-associated Tumors
2
Cholangiocarcinoma
2
Breast Neoplasms
2
Bites and Stings
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Interventions
pembrolizumab
8
Nivolumab
6
Ipilimumab
3
toripalimab
2
atezolizumab
2
Specimen Handling
2
Celecoxib
2
relatlimab
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
camrelizumab
1
avelumab
1
XELOX
1
Neoadjuvant Therapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Interleukin-2
1
Induction Chemotherapy
1
Immunotherapy
1
Immune Checkpoint Inhibitors
1
IMM-101
1
E7777 fusion protein
1
Docetaxel
1
Diffusion Tensor Imaging
1
DNA Mismatch Repair
1
DEAE-Dextran
1
Cyclophosphamide
1
Colonoscopy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Turcot syndrome
×
Immune Checkpoint Inhibitors
×
1 year
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled